Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAPIS: Long-acting HIV PrEP in South Africa
NCT06250504Phase 3Recruiting
- Sponsor
- Africa Health Research Institute
- Start
- Feb 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabotegravir and dapivirine in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Africa Health Research Institute. Primary endpoints: Uptake PrEP at 20 months and Retention on PrEP at 14 months. Started Feb 2024; status: recruiting.
02
Drugs
cabotegravirdapivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06250504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06250504.